Armistice Capital, LLC and Steven Boyd filed a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 3,669,775 shares of Estrella ImmunoPharma, Inc. common stock as of September 30, 2026.
Key Highlights
- Reporting persons: Armistice Capital, LLC (Delaware) and Steven Boyd (United States) filed jointly as the "Reporting Persons."
- Shares beneficially owned: 3,669,775 shares of common stock, par value $0.0001 per share (CUSIP 297584104).
- Percent of class: 8.44% of Estrella ImmunoPharma's outstanding common stock.
- Voting and dispositive power: All 3,669,775 shares are held with shared voting power and shared dispositive power; sole voting and sole dispositive power are each reported as 0.
- Direct holder: The shares are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company and investment advisory client of Armistice Capital.
- Event date: The date of the event requiring this filing is September 30, 2026.
Armistice Capital's Ownership Structure in Estrella ImmunoPharma
According to the Schedule 13G filed on November 16, 2026, Armistice Capital, LLC serves as the investment manager of Armistice Capital Master Fund Ltd., which is the direct holder of the reported shares of Estrella ImmunoPharma, Inc. (NASDAQ:ESLA). Pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities held by the Master Fund and, as a result, the filing states it "may be deemed to beneficially own the securities of the Issuer held by the Master Fund." Steven Boyd, as the managing member of Armistice Capital, is likewise reported to "may be deemed to beneficially own the securities of the Issuer held by the Master Fund."
The filing notes that the Master Fund "specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital." The Master Fund is identified as having the right to receive dividends from, or proceeds from the sale of, the reported securities. Neither reporting person holds any sole voting or sole dispositive power over the shares; both figures are reported as 0 in the filing.
The certifications included in the filing state that, to the best of the signatories' knowledge and belief, the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." Armistice Capital is classified as an investment adviser and other (IA, OO), while Steven Boyd is classified as a holding company and individual (HC, IN). The filing is signed by Steven Boyd as Managing Member of Armistice Capital and in his individual capacity, dated November 16, 2026.
What Was Disclosed
Armistice Capital, LLC and Steven Boyd disclosed beneficial ownership of 3,669,775 shares, representing 8.44% of Estrella ImmunoPharma's common stock, as of September 30, 2026, with all shares held through Armistice Capital Master Fund Ltd. via shared voting and dispositive power.




Please wait processing your request...